Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Given Consensus Rating of "Moderate Buy" by Analysts

Key Points

• Inventiva S.A. Sponsored ADR (NASDAQ:IVA) has received a consensus recommendation of "Moderate Buy" from six research firms, with five analysts recommending to buy the stock.
• The average twelve-month price target for Inventiva stock is $14.83, reflecting optimism from several analysts who have recently updated their ratings.
• Institutional investors currently hold 19.06% of Inventiva's shares, with a hedge fund recently acquiring 10,000 shares valued at approximately $32,000.

Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Get Free Report) has been given an average rating of "Moderate Buy" by the six research firms that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $14.8333.

Several equities research analysts recently commented on the stock. HC Wainwright assumed coverage on shares of Inventiva in a research note on Wednesday, September 3rd. They set a "buy" rating and a $20.00 price objective on the stock. Piper Sandler started coverage on shares of Inventiva in a research note on Wednesday, August 27th. They issued an "overweight" rating and a $26.00 target price on the stock. Finally, Guggenheim upped their target price on shares of Inventiva from $9.00 to $13.00 and gave the stock a "buy" rating in a research note on Tuesday, September 2nd.

Inventiva Price Performance

Shares of NASDAQ IVA traded down $0.38 during midday trading on Friday, hitting $5.64. 70,252 shares of the company traded hands, compared to its average volume of 25,173. Inventiva has a 12-month low of $1.53 and a 12-month high of $6.50. The stock has a 50-day moving average price of $4.41 and a 200 day moving average price of $3.67.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Inventiva stock. Creative Planning acquired a new stake in shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,000 shares of the company's stock, valued at approximately $32,000. Institutional investors own 19.06% of the company's stock.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.